Independent research review network
Appears in 1 story · Last updated Nov 22, 2026
Published a skeptical April 2026 review of the drug class
Eisai and Biogen screened 623 spinal fluid samples from the Clarity AD trial for α-synuclein, the protein that clumps into Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Twenty percent of the amyloid-positive volunteers carried it, twice the rate of the amyloid-negative group. Among the 82 carriers who received lecanemab, decline on the CDR-SB dementia scale ran 41% slower than placebo, against 27% across the whole trial.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?